Skip to main content

Share story

Infrastructure Security

AMD says EPYC processors power Google's confidential TPU infrastructure

AMD says EPYC processors power Google's confidential TPU infrastructure Image: Primary
AMD announced that its fifth-generation EPYC processors power the host infrastructure for Google Cloud's TPU 8tx, supporting hardware protections for sensitive AI workloads. The CPUs prepare data, coordinate workloads and manage communication with the AI accelerators. AMD says its Secure Encrypted Virtualization technology extends protection from the CPU to connected accelerators. The system verifies an accelerator's identity and security configuration before granting access to protected memory, helping keep prompts, model weights and intermediate data encrypted in CPU memory and in transit. Hardware isolation protects accelerator execution. AMD notes that server manufacturers or cloud providers must enable its security features for them to operate.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from Advanced Micro Devices, Inc. (AMD) Press Releases and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
Capital
Capital

Nominal raises $240 million at a $3 billion valuation

Nominal has raised $240 million at a $3 billion valuation, triple its valuation in a funding round earlier this year, Bloomberg reports. The startup builds software to make manufacturing more efficient.

Capital Products
Capital Products

Onodrim raises $300M to acquire European defence and industrial suppliers

Amsterdam-based Onodrim Industries has raised $300M in a round led by Lux Capital, valuing the defence group at $1.3bn, the company said Monday. Other investors include General Catalyst, Lakestar and Altimeter. The financing follows its €40M seed round in February.

Capital
Capital

SRTD Biotech raises €31.5 million for targeted RNA therapies

SRTD Biotech has completed an oversubscribed €31.5 million seed financing to develop RNA therapies designed to act selectively inside diseased cells. Mérieux Equity Partners led the round, with NRW.BANK and Boehringer Ingelheim Venture Fund joining as co-leads.